A Review of the Pharmacokinetics of Abacavir
Yuen, Geoffrey J., Weller, Steve, Pakes, Gary E.
Published in Clinical pharmacokinetics (01.01.2008)
Published in Clinical pharmacokinetics (01.01.2008)
Get full text
Journal Article
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Published in AIDS research and therapy (28.03.2008)
Published in AIDS research and therapy (28.03.2008)
Get full text
Journal Article
Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy
ERON, Joseph J, PARK, Jeong-Gun, HAUBRICH, Richard, AWEEKA, Francesca, BASTOW, Barbara, PAKES, Gary E, SONG YU, HULIN WU, RICHMAN, Douglas D
Published in Antimicrobial Agents and Chemotherapy (01.06.2009)
Published in Antimicrobial Agents and Chemotherapy (01.06.2009)
Get full text
Journal Article
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B5701 Screening as a Risk‐Mitigation Measure
Stainsby, Chris M., Perger, Teodora M., Vannappagari, Vani, Mounzer, Karam C., Hsu, Ricky K., Henegar, Cassidy E., Oyee, James, Urbaityte, Rimgaile, Lane, Charlotte E., Carter, Lindsay M., Pakes, Gary E., Shaefer, Mark S.
Published in Pharmacotherapy (01.01.2019)
Published in Pharmacotherapy (01.01.2019)
Get full text
Journal Article
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
Keiser, Philip H, Sension, Michael G, DeJesus, Edwin, Rodriguez, Allan, Olliffe, Jeffrey F, Williams, Vanessa C, Wakeford, John H, Snidow, Jerry W, Shachoy-Clark, Anne D, Fleming, Julie W, Pakes, Gary E, Hernandez, Jaime E
Published in BMC infectious diseases (12.01.2005)
Published in BMC infectious diseases (12.01.2005)
Get full text
Journal Article
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy
Cespedes, Michelle S, Castor, Delivette, Ford, Susan L, Lee, Doreen, Lou, Yu, Pakes, Gary E, Aberg, Judith A
Published in Journal of acquired immune deficiency syndromes (1999) (15.04.2013)
Published in Journal of acquired immune deficiency syndromes (1999) (15.04.2013)
Get more information
Journal Article
Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials
MOORE, K. H. P, YUEN, G. J, HUSSEY, E. K, PAKES, G. E, ERON, J. J, BARTLETT, J. A
Published in Antimicrobial Agents and Chemotherapy (01.12.1999)
Published in Antimicrobial Agents and Chemotherapy (01.12.1999)
Get full text
Journal Article
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
Young, Benjamin, Squires, Kathleen E, Ross, Lisa L, Santiago, Lizette, Sloan, Louis M, Zhao, Henry H, Wine, Brian C, Pakes, Gary E, Margolis, David A, Shaefer, Mark S
Published in AIDS research and human retroviruses (01.02.2013)
Published in AIDS research and human retroviruses (01.02.2013)
Get more information
Journal Article
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
Swindells, Susan, Cohen, Calvin J, Berger, Daniel S, Tashima, Karen T, Liao, Qiming, Pobiner, Bonnie F, Snidow, Jerry W, Pakes, Gary E, Hernandez, Jaime E
Published in BMC infectious diseases (08.04.2005)
Published in BMC infectious diseases (08.04.2005)
Get full text
Journal Article
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
Squires, Kathleen E, Young, Benjamin, Santiago, Lizette, Dretler, Robin H, Walmsley, Sharon L, Zhao, Henry H, Pakes, Gary E, Ross, Lisa L, Shaefer, Mark S
Published in HIV/AIDS (Auckland) (01.01.2017)
Published in HIV/AIDS (Auckland) (01.01.2017)
Get full text
Journal Article
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
Ross, Lisa L, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Horton, Joseph H, Pappa, Keith A, Lancaster, C Tracey, Pakes, Gary E, Smith, Kimberly Y
Published in AIDS research and human retroviruses (01.04.2010)
Published in AIDS research and human retroviruses (01.04.2010)
Get more information
Journal Article
Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
Horizon, Arash A, Joseph, Robert J, Liao, Qiming, Ross, Steven T, Pakes, Gary E
Published in HIV/AIDS (Auckland) (28.06.2011)
Published in HIV/AIDS (Auckland) (28.06.2011)
Get full text
Journal Article
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Hicks, Charles B, DeJesus, Edwin, Sloan, Louis M, Sension, Michael G, Wohl, David A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Published in AIDS research and human retroviruses (01.04.2009)
Published in AIDS research and human retroviruses (01.04.2009)
Get more information
Journal Article
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz
PHAM, Paul A, HENDRIX, Craig W, FLEXNER, Charles, BARDITCH-CROVO, Patricia, PARSONS, Teresa, KHAN, Wasif, PARISH, Michelle, RADEBAUGH, Christine, CARSON, Kathryn A, PAKES, Gary E, QAQISH, Roula
Published in Antiviral therapy (01.01.2007)
Published in Antiviral therapy (01.01.2007)
Get full text
Journal Article
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population
Rawlings, M Keith, Klein, Jennifer, Klingler, Edna P Toubes, Queen, Ejeanée, Rogers, Lauren, Yau, Linda H, Pappa, Keith A, Pakes, Gary E
Published in HIV/AIDS (Auckland) (01.01.2011)
Published in HIV/AIDS (Auckland) (01.01.2011)
Get full text
Journal Article
Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours
Moodley, D, Pillay, K, Naidoo, K, Moodley, J, Johnson, M A, Moore, K H, Mudd, Jr, P N, Pakes, G E
Published in Journal of clinical pharmacology (01.07.2001)
Published in Journal of clinical pharmacology (01.07.2001)
Get more information
Journal Article
Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption
Moore, K H, Shaw, S, Laurent, A L, Lloyd, P, Duncan, B, Morris, D M, O'Mara, M J, Pakes, G E
Published in Journal of clinical pharmacology (01.06.1999)
Published in Journal of clinical pharmacology (01.06.1999)
Get more information
Journal Article
Correlation between self-reported Adherence to highly active antiretroviral therapy (HAART) and virologic outcome
DEMASI, Ralph A, GRAHAM, Neil M, TOLSON, Jerry M, PHAM, Sissi V, CAPUANO, George A, FISHER, Robin L, SHAEFER, Mark S, PAKES, Gary E, SAWYERR, Gosford A, ERON, Joseph J
Published in Advances in therapy (01.07.2001)
Published in Advances in therapy (01.07.2001)
Get full text
Journal Article